The purpose of this study is to determine what side effects CP 870,893 may cause when given
with an immune stimulant called Oncovir poly IC:LC along with a melanoma vaccine. The CP
870,893, the Oncovir poly IC:LC and the melanoma vaccine are investigational drugs that have
not been combined in patients before, and that have not been approved for sale by the Food
and Drug Administration. The Oncovir poly IC:LC is intended to stimulate the body's immune
system.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
National Cancer Institute (NCI) Oncovir, Inc. Pfizer